These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16473368)

  • 1. Recapitulation and design of protein binding peptide structures and sequences.
    Sood VD; Baker D
    J Mol Biol; 2006 Mar; 357(3):917-27. PubMed ID: 16473368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Framework for Prediction of Peptide Sequences That May Mediate Multiple Protein Interactions in Cancer-Associated Hub Proteins.
    Sarkar D; Patra P; Ghosh A; Saha S
    PLoS One; 2016; 11(5):e0155911. PubMed ID: 27218803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual interaction profiles of proteins.
    Wollacott AM; Desjarlais JR
    J Mol Biol; 2001 Oct; 313(2):317-42. PubMed ID: 11800560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
    Burch LR; Scott M; Pohler E; Meek D; Hupp T
    J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational studies and peptidomimetic design for the human p53-MDM2 complex.
    Zhong H; Carlson HA
    Proteins; 2005 Jan; 58(1):222-34. PubMed ID: 15505803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides.
    Wiedemann U; Boisguerin P; Leben R; Leitner D; Krause G; Moelling K; Volkmer-Engert R; Oschkinat H
    J Mol Biol; 2004 Oct; 343(3):703-18. PubMed ID: 15465056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of beta-catenin recognition by Tax-interacting protein-1.
    Zhang J; Yan X; Shi C; Yang X; Guo Y; Tian C; Long J; Shen Y
    J Mol Biol; 2008 Dec; 384(1):255-63. PubMed ID: 18835279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple physical model for the prediction and design of protein-DNA interactions.
    Havranek JJ; Duarte CM; Baker D
    J Mol Biol; 2004 Nov; 344(1):59-70. PubMed ID: 15504402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of affinity peptides from natural protein ligands: A study of the cardiac troponin complex.
    Chandra D; Sankalia N; Arcibal I; Banta S; Cropek D; Karande P
    Biopolymers; 2014 Jan; 102(1):97-106. PubMed ID: 24436041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why ligand cross-reactivity is high within peptide recognition domain families? A case study on human c-Src SH3 domain.
    He P; Wu W; Wang HD; Liao KL; Zhang W; Lv FL; Yang K
    J Theor Biol; 2014 Jan; 340():30-7. PubMed ID: 24021866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural basis of peptide-protein binding strategies.
    London N; Movshovitz-Attias D; Schueler-Furman O
    Structure; 2010 Feb; 18(2):188-99. PubMed ID: 20159464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain.
    Hou T; Chen K; McLaughlin WA; Lu B; Wang W
    PLoS Comput Biol; 2006 Jan; 2(1):e1. PubMed ID: 16446784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain.
    Hou T; Zhang W; Case DA; Wang W
    J Mol Biol; 2008 Feb; 376(4):1201-14. PubMed ID: 18206907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design.
    Togashi M; Borngraeber S; Sandler B; Fletterick RJ; Webb P; Baxter JD
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):127-37. PubMed ID: 15860255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based prediction of the peptide sequence space recognized by natural and synthetic PDZ domains.
    Smith CA; Kortemme T
    J Mol Biol; 2010 Sep; 402(2):460-74. PubMed ID: 20654621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
    Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
    J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
    Pisabarro MT; Serrano L; Wilmanns M
    J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the SH2 domain from the adaptor protein SHC: a model for peptide binding based on X-ray and NMR data.
    Mikol V; Baumann G; Zurini MG; Hommel U
    J Mol Biol; 1995 Nov; 254(1):86-95. PubMed ID: 7473762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.